Share This Link

The client has peptic ulcer disease who has been prescribed sucralfate and an antacid. The client’s pain pattern, occurring 2 hours after meals, at night, and relieved by food, is typical of a duodenal ulcer. Sucralfate works by forming a protective barrier over the ulcer site, while antacids help neutralize gastric acid for symptom relief. Proper administration timing and technique are essential to ensure the effectiveness of both medications and promote ulcer healing.

Rationale:

• Shake the suspension thoroughly before administration: Sucralfate suspension must be shaken well before administration to ensure the medication is evenly distributed and the correct dose is received. If not mixed properly, the concentration may be inconsistent, reducing therapeutic effectiveness. Since sucralfate acts locally by coating the ulcer, proper preparation is necessary for full mucosal protection. Consistent dosing improves healing and reduces irritation.

• Avoid taking the antacid within 30 min of the sucralfate: Antacids can interfere with the action of sucralfate by altering gastric pH and preventing it from properly adhering to the ulcer surface. Sucralfate requires an acidic environment to form its protective barrier over the ulcer. Taking antacids too close to sucralfate administration reduces this effect and delays healing. Spacing the medications apart helps both drugs work effectively without reducing each other’s benefits.

• Take the sucralfate with meals: Sucralfate should be taken on an empty stomach, usually 1 hour before meals and at bedtime, not with meals. This allows the medication to bind directly to the ulcer surface without interference from food. Taking it with meals reduces contact with the ulcer and decreases its protective effect. Proper timing is essential for maximum therapeutic benefit and symptom control.

• Discontinue the sucralfate as soon as ulcer manifestations subside: Sucralfate should not be stopped as soon as symptoms improve because ulcer healing continues even after pain decreases. Premature discontinuation can result in incomplete healing and increase the risk of recurrence. Clients should complete the full prescribed course, often several weeks, to ensure adequate mucosal repair. Symptom relief does not necessarily mean the ulcer has fully healed.

This question focuses on identifying priority assessment findings in a client who has transitioned from manifestations of hypothyroidism to signs of severe hyperthyroidism, likely indicating thyrotoxicosis or thyroid storm. Six months ago, the client showed classic hypothyroid findings such as lethargy, weight gain, bradycardia, constipation, and cold dry skin, for which levothyroxine was prescribed. Today, the client presents with tachycardia, fever, palpitations, chest pain, insomnia, and hyperactive bowel sounds, suggesting excessive thyroid hormone activity. Priority assessment should focus on findings that threaten life first, especially cardiovascular instability and hyperthermia.

Rationale:

• Pain (Chest pain): Chest pain is a priority because excessive thyroid hormone increases myocardial oxygen demand and significantly raises cardiac workload through tachycardia and hypertension. This can precipitate angina, dysrhythmias, or even myocardial infarction, especially when accompanied by palpitations and a heart rate of 118/min. Chest pain indicates possible cardiovascular compromise, which requires immediate evaluation because impaired circulation can rapidly become life-threatening.

• Temperature: An elevated temperature of 38.1°C (100.6°F) is significant because fever in the presence of hyperthyroid symptoms may indicate thyroid storm, a life-threatening endocrine emergency. Thyroid storm causes a hypermetabolic state that rapidly increases oxygen consumption and systemic stress. Hyperthermia can progress quickly and contribute to dehydration, neurologic changes, and cardiovascular collapse. Temperature must be prioritized because it reflects the severity of systemic involvement.

• Bowel sounds: Hyperactive bowel sounds and frequent loose stools are expected findings in hyperthyroidism due to increased metabolic activity and accelerated gastrointestinal motility. Although they contribute to discomfort and possible fluid loss, they are not immediately life-threatening compared to cardiac complications or possible thyroid storm. These findings are important to monitor, but they do not take priority.

• Heart rate: A heart rate of 118/min is significant and reflects increased sympathetic stimulation from excess thyroid hormone, but chest pain takes higher priority because it signals possible actual cardiac ischemia or compromised perfusion. Tachycardia alone can often be monitored and treated, while chest pain may represent active myocardial injury requiring immediate intervention.

• Weight: The significant weight loss from 75 kg to 59.1 kg reflects increased metabolism associated with hyperthyroidism and is useful for evaluating disease progression. However, weight change occurs gradually and does not represent an immediate threat to life. It supports the diagnosis but does not require urgent intervention compared with tachycardia and fever. Priority nursing care focuses first on acute instability before long-term nutritional concerns.

• Skin: Warm, moist skin is a common manifestation of hyperthyroidism due to increased heat production and peripheral vasodilation. While this helps confirm the endocrine imbalance, it is not a critical indicator requiring urgent intervention. Skin changes are expected secondary findings and are less urgent than signs of cardiovascular stress or hyperthermia. Assessment priority should remain with findings that indicate possible thyroid storm.

The client has a recent history of myocardial infarction and is prescribed warfarin, an anticoagulant used to prevent thromboembolic events. They have also been taking ibuprofen every 6 hours for several days for symptom relief. The combination of warfarin and NSAIDs significantly increases the risk of bleeding, particularly gastrointestinal bleeding, making medication safety and adverse effect recognition a priority nursing responsibility.

Rationale:

• GI bleeding: Warfarin works by inhibiting vitamin K–dependent clotting factors, which prolongs clotting time and increases bleeding risk. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that can irritate the gastric mucosa and impair platelet aggregation. When taken together, these effects significantly raise the likelihood of gastrointestinal bleeding, even if the client does not yet show visible bleeding signs. Early symptoms such as lethargy may also suggest occult blood loss or worsening anticoagulation effects.

• Concurrent medication use: The major concern is the concurrent use of warfarin and ibuprofen, not the sore throat or reduced activity. NSAIDs increase bleeding risk by both damaging the gastrointestinal lining and interfering with platelet function, while warfarin reduces clot formation systemically. This interaction is clinically significant and requires prompt intervention, education, and likely discontinuation of ibuprofen.

• Deep vein thrombosis: Although reduced activity can increase the risk of venous stasis and thrombosis, this client is already taking warfarin, which decreases the risk of clot formation. There is no evidence of leg pain, swelling, warmth, or unilateral edema to suggest developing DVT. The more immediate concern is excessive anticoagulation and bleeding rather than clot formation. The medication interaction presents a higher-priority safety issue than temporary reduced mobility.

• Fluid volume excess: There are no findings supporting fluid volume excess such as peripheral edema, crackles, jugular venous distention, or rapid weight gain. Lung sounds are clear, heart rhythm is regular, and the abdomen is soft and nondistended. The client’s symptoms of lethargy and headache are more concerning for medication-related complications rather than fluid retention.

• Activity level: The client reports lying in bed most of the day because of illness, but this short-term reduction in activity is not the primary safety concern. While immobility can contribute to clotting risk, warfarin therapy already provides anticoagulation protection. Compared to the dangerous interaction between ibuprofen and warfarin, decreased activity is a less urgent contributor to complications.

• Recent illness: The sore throat, headache, and lethargy may explain why the client used ibuprofen, but the illness itself does not directly create the highest risk identified in this scenario. There is no fever or evidence of severe infection causing complications such as dehydration or organ dysfunction. The major clinical issue is how the self-treatment with ibuprofen interacts with prescribed warfarin.